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Background: Achieving optimal symptom control with minimal side effects is a major goal in clinical practice.
Dual-agent dopamine receptor agonist (DA) therapy in Parkinson’s disease (PD) may represent a promising
approach to treatment, as the combination of different pharmacokinetic/pharmacological profiles may result in a
lesser need for high dosages and, accordingly, may be well tolerated. The objective of the current study was to
investigate safety and efficacy of rotigotine transdermal system as add-on to oral DA in patients with advanced PD
inadequately controlled with levodopa and low-dose oral DA.
Methods: PD0015 was an open-label, multinational study in patients with advanced-PD and sleep disturbance or
early-morning motor impairment. Patients were titrated to optimal dose rotigotine (≤8 mg/24 h) over 1–4 weeks
and maintained for 4–7 weeks (8-week treatment). Dosage of levodopa and oral DA (pramipexole ≤1.5 mg/day,
ropinirole ≤6.0 mg/day) was stable. Primary variable was Clinical Global Impressions (CGI) item 4: side effects,
assessing safety. Other variables included adverse events (AEs), Patient Global Impressions of Change (PGIC), Unified
Parkinson’s Disease Rating Scale (UPDRS) II and III, Parkinson’s Disease Sleep Scale (PDSS-2), Pittsburgh Sleep Quality
Index (PSQI), and “off” time.
Results: Of 90 patients who received rotigotine, 79 (88%) completed the study; 5 (6%) withdrew due to AEs. Most
(83/89; 93%) had a CGI-4 score <3 indicating that rotigotine add-on therapy did not interfere with functioning;
6 (7%) experienced drug-related AEs that interfered with functioning (score ≥3). AEs occurring in ≥5% were
application site pruritus (13%), dizziness (10%), orthostatic hypotension (10%), nausea (8%), dyskinesia (8%), and
nasopharyngitis (6%). Numerical improvements in motor function (UPDRS III), activities of daily living (UPDRS II),
sleep disturbances (PDSS-2, PSQI), and reduction in “off” time were observed. The majority (71/88; 81%) improved
on PGIC.
Conclusions: Addition of rotigotine transdermal system to low-dose oral DA in patients with advanced-PD was
feasible and may be associated with clinical benefit.
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Treatment with chronic levodopa for the symptoms of ad-
vanced Parkinson's disease (PD) is often associated with the
development of motor fluctuations and dyskinesia, which
gradually worsen as the disease progresses [1,2]. These limi-
tations of levodopa therapy have been managed by the use
of concomitant treatment with non-ergot derived dopa-
mine receptor agonists (DAs). The DAs have some advan-
tages over levodopa, including longer half-lives [3], which
may reduce or delay the onset of motor complications.
Achieving optimal symptom control with minimal side ef-
fects is a major goal in clinical practice. Dual-agent DA
therapy in PD may represent a promising approach to treat-
ment, as the combination of different pharmacokinetic/
pharmacological profiles may result in a lesser need for
high dosages and, accordingly, may be well tolerated [4-6].
Rotigotine is a non-ergot derived DA with activity
across D1 through D5 receptors as well as select adren-
ergic and serotonergic sites [7]. Continuous transdermal
delivery of rotigotine maintains stable plasma levels over
24 hours with a single daily application [8], thus avoid-
ing plasma level peaks and troughs associated with more
pulsatile oral drug delivery. Symptoms of some PD pa-
tients may not be adequately controlled over the entire
24-h range with existing oral DA treatment. Since roti-
gotine transdermal system maintains stable plasma con-
centration over 24 h, add-on rotigotine may supplement
the effects of oral DAs. Activation of the D1 receptor is
unique to rotigotine among the non–ergot-derived DAs;
pramipexole and ropinirole have been shown to act at
the D2 and D3 receptors, but exhibit little or no affinity
at the D1 receptor [9,10]. A synergistic interaction may
exist between D1 and D2 receptors; a D1 receptor agon-
ist has been shown to act synergistically with a D2 re-
ceptor agonist to prolong the motor stimulation induced
by each agonist alone in the MPTP-lesioned monkey
model of PD [11]. Thus, as a result of their different
pharmacokinetic/pharmacological properties, there may
be benefits of dual treatment with transdermally deliv-
ered rotigotine and oral ropinirole or pramipexole. Sig-
nificant treatment effects of rotigotine transdermal
system have been observed in double-blind, placebo-
controlled studies as add-on therapy to levodopa in
advanced-stage PD [12,13] (improvements in motor fluc-
tuations; i.e., “on” and “off” time), and also in patients
with PD and unsatisfactory control of early-morning
motor function (improvements in early-morning motor
function and sleep disturbance [a non-motor symptom
of PD]) [14]. In addition, improvements in motor func-
tion and motor fluctuations have been demonstrated
with 3-times-daily oral immediate-release (IR) ropinirole
or pramipexole, or their once-daily oral extended-release
(ER) formulations in combination with levodopa in pa-
tients with advanced PD [15,16].The objective of this study was to investigate the safety
and efficacy of rotigotine transdermal system as add-on
to therapy with low-dose pramipexole or ropinirole, in
patients with advanced PD. Enrolled patients were insuf-
ficiently controlled with levodopa and low-dose oral DA,
identified as experiencing motor complications and sleep
disturbance or early-morning motor impairment.
Methods
Patients
Patients enrolled in the PD0015 study included men and
women, aged 30–80 years, with idiopathic PD of longer
than 3 years’ duration, and Hoehn and Yahr stage II-IV. PD
was defined by the presence of bradykinesia and at least
one of the following: resting tremor, rigidity, or impairment
of postural reflexes. In addition, all patients included had
to be taking levodopa (immediate or controlled release,
and at a stable dose) in combination with benserazide or
carbidopa, and a stable low dose of IR or ER pramipexole
(≤1.5 mg/day) or ropinirole (≤6.0 mg/day) for at least
28 days before baseline. Patients had to experience motor
fluctuations (“wearing off”, “on-off” phenomena, delayed
“on” or “non-on”) or dyskinesia, sleep disturbance or early-
morning motor impairment, as determined by the investi-
gator, and nocturia for at least 3 nights within 7 days before
baseline. At the screening visit, patients were instructed to
differentiate between “off” and “on” states and symptoms of
“troublesome dyskinesia” for diary recordings. Patients com-
pleted 7 days of diary recordings before beginning study
treatment; four of the diaries had to be determined “valid”
by the investigator for the patient to be eligible. Permitted
PD medications included anticholinergics, monoamine oxi-
dase B (MAO-B) inhibitors, N-methyl-D-aspartate (NMDA)
antagonists (e.g., amantadine), and entacapone; permitted
CNS active drugs included sedatives, antidepressants, anxio-
lytics, hypnotics. All permitted drugs were required to be at
stable doses for at least 28 days prior to baseline, and were
to remain stable for the duration of the study.
Patients with clinically significant hepatic or renal impair-
ment were excluded. Prohibited medications included DAs
other than pramipexole or ropinirole, MAO-A inhibitors,
dopamine-releasing substances, dopamine-modulating sub-
stances, tolcapone, budipine, dopamine receptor antagonists
(antiemetics [other than domperidone, e.g., metoclopra-
mide], and neuroleptics). The study was conducted in ac-
cordance with Good Clinical Practice and the Declaration
of Helsinki. The study protocol and amendments were ap-
proved by the Institutional Review Board of all 21 centers
(Additional file 1: Table S1). All patients provided written,
informed consent before study participation.
Study design and procedures
PD0015 (ClinicalTrials.gov:NCT01723904) was a Phase
IIIb, open-label, single-arm study in patients with advanced
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centers enrolled patients, who applied at least one rotigo-
tine patch, in South Korea, Malaysia, Taiwan, Australia, and
Singapore.
Baseline data were recorded following a screening
period of up to 4 weeks. Rotigotine was administered as
once-daily patches of three different sizes; patches pro-
vided nominal doses of rotigotine 2 mg/24 h (10 cm2),
4 mg/24 h (20 cm2), or 6 mg/24 h (30 cm2). The study
consisted of a 1-4-week titration and 4-7-week mainten-
ance period (total of 8-week treatment); patients were
titrated in weekly increments of 2 mg/24 h rotigotine
to their optimal (or maximal allowed) dose (up to 8 mg/
24 h) (Additional file 2: Figure S1). The optimal dose
was defined as the dose at which both the investigator
and patient felt that sleep disturbance or early-morning
motor impairment was controlled. As this was the first
study of rotigotine used concomitantly with a DA, the
permitted upper doses were considered based on safety
and the potential for overdose from concurrent use of
DAs, in reference to the equivalent dosing regimens
(Additional file 3: Table S2) [4,12,17]. The upper limit
was determined as 1.5 mg/day for pramipexole (approved
dose 4.5 mg/day), 6 mg/day for ropinirole (approved dose
24 mg/day), and 8 mg/24 h for rotigotine (EU-approved
dose 16 mg/24 h). Using these upper dose limits, the com-
bined total DA dose would not exceed the maximum ap-
proved dose of any of the DAs (see the equivalent dosing
regimens in Additional file 3: Table S2). During titration, if
AEs occurred that might be the result of excessive dopa-
minergic stimulation, rotigotine could be back-titrated
once to the previous dose (and the patient was requested
to visit the study site within 1 week for a safety assess-
ment), the patient began the maintenance phase immedi-
ately at the back-titrated dose. Dose adjustments were not
permitted during maintenance. Clinic visits occurred at
screening, baseline, and weeks 1, 2, 3, 4, 5, and 8 of titra-
tion/maintenance. Patients who withdrew prematurely
were asked to return for a withdrawal visit.
Outcome measures
The primary variable was safety, as assessed using the
Clinical Global Impressions (CGI) item 4 score (side
effects) at the end of maintenance: 1 = “None”, 2 =
“Not significantly interfering with patient’s functioning”,
3 = “Significantly interfering with the patient’s function-
ing”, and 4 = “Side effects outweigh therapeutic efficacy”.
Other safety evaluations included extent of rotigotine
exposure, and treatment-emergent adverse events (AEs,
regardless of a causal relationship). In addition, AEs of
special interest (those typical of dopaminergic stimula-
tion, use of a transdermal patch, or complications re-
lated to PD) were pre-identified and assessed. The AEs
of special interest were pre-identified as application sitereactions, nausea and vomiting, somnolence, psychosis,
sleep attacks/sudden onset of sleep, obsessive-compulsive
disorder/impulse-control disorder, postural deformities,
freezing gait, and perception disturbances that required
atypical antipsychotic treatment. In addition, the modified
Minnesota Impulsive Disorder Interview was used to
prompt the investigators and patients to monitor the
emergence of impulse control disorders. Finally, physical
and neurological examinations, changes in laboratory
tests, vital signs, 12-lead electrocardiography (ECG), and
the Columbia-Suicide Severity Rating Scale (C-SSRS) were
also assessed.
Efficacy variables included outcomes assessing motor
symptoms, motor fluctuations, non-motor symptoms
(sleep disturbance), and quality of life. Change from
baseline to end of maintenance was assessed for Unified
Parkinson’s Disease Rating Scale (UPDRS) Parts II (ac-
tivities of daily living [ADL]; mean for the “on” and “off”
state), and III (motor examination; in the “on” state);
absolute time spent "off" and absolute time spent "on"
without troublesome dyskinesia (assessed from patient
diaries); Parkinson's Disease Sleep Scale version 2 (PDSS-2);
global score of the Pittsburgh Sleep Quality Index (PSQI);
Patient Global Impression of Change (PGIC; change from
baseline in activity limitations, symptoms, emotions, and
overall quality of life; PGIC score 1 = “Very much im-
proved”, 2 = “Much improved”, 3 = “Minimally improved”,
4 = “No change”, 5 = “Minimally worse”, 6 = “Much worse”,
7 = “Very much worse”), and the 8-item short-form Parkin-
son’s Disease Questionnaire (PDQ-8; assessing PD-related
quality of life). Other variables included number of awaken-
ings during the night and number of nocturias, assessed
from patient diaries.
Statistical analyses
The primary variable (CGI item 4 score) was analyzed by
the safety set (all enrolled patients who had at least one
rotigotine patch applied during the treatment period),
using last observation carried forward (LOCF). With the
exception of time spent “off”, efficacy variables were ana-
lyzed using the full analysis set (FAS; all patients who ap-
plied at least one rotigotine patch, and had a baseline and
at least one post-baseline UPDRS III assessment), with
LOCF. Time spent “off” was analyzed using a subgroup of
the FAS comprising patients who recorded time spent
“off” at baseline in the patient diary. Efficacy variables were
summarized with univariate statistics (mean ± SD), and
95% confidence intervals (CI) were calculated for changes
from baseline (i.e., before and after rotigotine add-on).
Results
Patient disposition and baseline characteristics
Of 112 patients who provided informed consent and
were screened, 22 failed screening, and 90 (80%) applied
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safety set. Of these 90 patients, 79 (88%) completed the
study; the remaining 11 patients (12%) withdrew prema-
turely due to AEs (n = 5) or for other reasons (n = 6).
Baseline demographic data are presented in Table 1.Safety and tolerability
Rotigotine exposure
The mean (±SD) duration of rotigotine exposure was
58.7 ± 14.9 days. A total of 84 patients (93%) entered
maintenance. The maintenance dose was 2 mg/24 h in
14 patients, 4 mg/24 h in 19 patients, 6 mg/24 h in 16
patients, and 8 mg/24 h in 35 patients (mean ± SD dose:
5.71 ± 2.28 mg/24 h). Of the 11 patients who discontin-
ued the study, six patients discontinued during the first
2 weeks of titration (at 2 mg/24 h), and the remaining
five patients discontinued after between 43 and 56 days
(i.e., approx. 6–8 weeks) of rotigotine treatment.
The dose of concomitant oral DA at baseline (as roti-
gotine converted dose) was 2 mg/24 h in 30 patients,Table 1 Patient demographics and baseline
characteristics, safety set
n = 90
Age, mean ± SD, years 61.3 ± 9.3
Female, n (%) 43 (48)













Levodopa dosage, mean ± SD, mg/day 547.2 ± 287.7
Oral dopamine receptor agonists dosage,
mean ± SD, mg/day
Pramipexole 0.9 ± 0.5 (n = 51; 57%)
Ropinirole 3.4 ± 2.0 (n = 39; 43%)
Oral dopamine receptor agonist formulation, n (%)
IR 54 (60)
ER 36 (40)
†Data missing from two patients.
SD: standard deviation; PD: Parkinson’s disease; IR: immediate release;
ER: extended release.4 mg/24 h in 29 patients, and 6 mg/24 h in 31 patients
(mean ± SD dose: 4.02 ± 1.66 mg/24 h). There was no
obvious relationship between the dose of oral DA and
dose of rotigotine (Additional file 4: Figure S2).
Primary outcome: safety assessed by CGI item 4
Most patients (83/89; 93%) had a score of <3 on CGI
item 4 (score of 1: 61/89; 69%, score of 2: 22/89; 25%) at
end of treatment, indicating that rotigotine add-on ther-
apy did not interfere with the patient’s functioning. At
end of maintenance, a total of six patients (7%) experi-
enced AEs, considered related to study drug by the in-
vestigator, that interfered with the patient’s functioning
(score ≥3). Three of these six patients were receiving
2 mg/24 h rotigotine at the time of the AE (Table 2).
Adverse events
Fifty eight patients (64%) experienced a total of 147 AEs.
AEs occurring with an overall incidence of 5% or higher
were application site pruritus reported by 12 patients
(13%), dizziness (9; 10%), orthostatic hypotension (9;
10%), nausea (7; 8%), dyskinesia (7; 8%), and nasophar-
yngitis (5; 6%). The incidence of AEs by 1) rotigotine
dose, and 2) oral DA dose is presented in Additional file
5: Table S3, and 3) by total DA dose is presented in Add-
itional file 6: Table S4.
Forty four patients (49%) experienced at least one AE
during titration, and 25 patients (30%) experienced at
least one AE during maintenance. The majority of AEs
were mild or moderate in intensity; six patients (7%) ex-
perienced at least one severe AE. Six serious AEs were
reported in five patients (6%): hallucination, subdural
hemorrhage, nasopharyngeal cancer, delirium, confu-
sional state, and urinary retention. Except for the hallu-
cination, all the events were considered unrelated to
rotigotine. No deaths were reported.
Five patients were prematurely withdrawn from the
study due to AEs (primary reason for withdrawal): dys-
kinesia (one patient), orthostatic hypotension (one pa-
tient), worsening of Parkinson’s disease (one patient),
subdural hemorrhage (one patient), dizziness, hyperhi-
drosis, insomnia, and nausea (one patient). One patient,
whose primary reason for withdrawal was due to non-
compliance, also discontinued the study due to an AE
(nausea). Down-titration of rotigotine was performed in
15 patients due to AEs.
Of the AEs of special interest, 22 (24%) patients expe-
rienced application site reactions, eight (9%) nausea and
vomiting (seven nausea [preferred term; PT], one vomit-
ing [PT]), four (4%) somnolence (three insomnia [PT],
one somnolence [PT]), four (4%) psychosis (two hallu-
cination [PT], one confusional state [PT], one delirium
[PT]), and one (1%) patient experienced obsessive-
compulsive disorder/impulse-control disorder.
Table 2 Primary outcome: CGI item 4† - Side effects interfering with patient’s functioning (score ≥3); FAS, LOCF
Treatment-related AE‡





















Moderate 8 mg/24 h
(maintenance)
No change Pramipexole ER
(0.75 mg/day
[3 mg/24 h])
11 mg/24 h 600 2; 3 years
Patient 2: Dyskinesia
(score 4)





6 mg/24 h 1425 3; 21 years
Patient 3: Nausea
(score 3)














6 mg/24 h 525 3; 6 years






No change Pramipexole IR
(0.25 mg/day
[1 mg])
9 mg/24 h 200 1; 9 years
Patient 6: Worsening
of PD (score 4)





5 mg/24 h 250 3; 11 years
†CGI item 4 score: 1 = none, 2 = not significantly interfering with patient’s functioning, 3 = significantly interfering with the patient’s functioning, 4 = side effects
outweigh therapeutic efficacy.
‡AE considered related to study treatment by the investigator.
*Rotigotine dose at AE onset plus converted rotigotine dose of oral DA.
AE: adverse events; IR: immediate release; ER: extended release; PD: Parkinson’s disease; LOCF: last observation carried forward; FAS: full analysis set.
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parameters, vital signs, ECGs, physical and neurological
examinations, or the C-SSRS.
Efficacy
Motor function (UPDRS III) and ability to carry out ADL
(UPDRS II) was improved following the addition of rotigo-
tine to the existing treatment with low oral DA (Figure 1).
Mean (±SD) UPDRS III score (“on” state) at baseline was
22.0 ± 11.3, and change from baseline to end of titration/
maintenance was −5.3 ± 8.3 (95% CI: −7.1, −3.6). Mean
(±SD) UPDRS II score (average of “on” and “off” states)
at baseline was 9.2 ± 4.5, and change from baseline
was −1.5 ± 3.8 (95% CI: −2.3, −0.7). The upper limits of
95% CI were below 0, suggesting an improvement in both
motor function and patients’ ability to carry out ADL. Im-
provements were also observed in absolute time spent
“off” and absolute time “on” without troublesome dyskin-
esia (Figure 1); mean (±SD) absolute “off” time change
from baseline was −2.1 ± 2.9 h (95% CI: –2.7, –1.5); mean
(±SD) absolute time spent “on” without troublesome dys-
kinesia change from baseline was 1.9 ± 3.1 h (95% CI: 1.2,
2.5). When considering the oral DA formulation,
there was no obvious difference in the improvement in
time spent “off” between the IR and ER formulations:
mean (±SD) absolute “off” time change from baseline
was −2.3 ± 3.0 (95% CI: −3.1,–1.4) for patients receiving IRoral DA (baseline 6.4 ± 2.5; n = 46), and −1.9 ± 2.7 (95%
CI: −2.8,–0.9) for patients receiving ER oral DA (baseline
6.0 ± 3.2; n = 34).
Improvements in items relating to disturbed sleep
(a non-motor symptom of PD) were observed, including
PDSS-2 total score, PSQI global score, number of
awakenings during the night, and number of nocturias
(Figure 2); mean (±SD) PDSS-2 total score change from
baseline was −3.2 ± 7.5 (95% CI: −4.8, −1.6), and mean
PSQI global score change from baseline was −0.7 ± 3.0
(95% CI: −1.4, −0.1). The mean (SD) change from baseline
in the number of awakenings during the night was −0.2 ±
0.6 (95% CI: −0.31, −0.04) and for nocturias was −0.2 ± 0.5
(95% CI: −0.3, −0.1). Improvements (i.e., upper limits of
95% CI below 0) were also observed following addition of
rotigotine treatment in two of the three domains of the
PDSS-2 (“disturbed sleep” and “motor symptoms at
night”), and six of 15 individual items. Worsening of the
individual PDSS-2 item of “distressing hallucination” was
observed (Figure 3).
The majority of patients reported an improvement on
the PGIC (71/88; 81%), with 29/88 (33%) reporting
“much improved” or “very much improved”, and only
3% (3/88) reporting a deterioration of “much worse” or
“very much worse”. Mean (±SD) PDQ-8 total score at
baseline was 29.4 ± 17.0, and change from baseline to
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Figure 1 UPDRS Parts II and III, UPDRS responder analysis, time spent “off”, and time spent “on” with troublesome dyskinesia, FAS,
LOCF. “Before rotigotine add-on”: baseline; “after rotigotine add-on”: end of maintenance. †95% CI does not contain zero (for change from
baseline [i.e., before to after rotigotine add-on]). UPDRS: Unified Parkinson’s Disease Rating Scale; FAS: full analysis set; LOCF: last observation
carried forward.
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suggesting an improvement in items assessing PD-related
quality of life.
Discussion
This open-label study was the first study of rotigotine
transdermal system used as an adjunct to treatment with
an oral DA. The majority of patients in this study were
Hoehn and Yahr stage II-III, and all were inadequately
controlled with a treatment regimen of levodopa and
low-dose oral pramipexole or ropinirole, presenting with
early-morning motor impairment or nocturnal sleep dis-
turbance. The study identified no major safety concerns

































Figure 2 PDSS-2 total score, PSQI global score, number of awakening
rotigotine add-on”: baseline; “after rotigotine add-on”: end of maintenance
to after rotigotine add-on]). PDSS-2: Parkinson’s Disease Sleep Scale; PSQI: P
tion carried forward.The addition of rotigotine was also associated with nu-
merical improvements in efficacy outcomes, including
motor function and sleep disturbances.
The addition of rotigotine was generally well tolerated,
with the majority of patients (93%) not experiencing
drug-related AEs that interfered with functioning, as
assessed by the primary outcome (CGI item 4). In the
patients experiencing drug-related AEs that interfered
with functioning (CGI item 4 ≥ 3), there was no obvious
relationship with the total DA dose (i.e., sum of rotigo-
tine and oral DA dose) or levodopa dose. Of note, the
majority of patients experienced an improvement on the
PGIC (81%), demonstrating that most patients consid-
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Figure 3 Change from baseline to end of maintenance in PDSS-2 domain and individual item scores, FAS, LOCF. †95% CI does not
contain zero (for change from baseline [i.e., before to after rotigotine add-on]). PDSS-2: Parkinson’s Disease Sleep Scale; FAS: full analysis set; LOCF:
last observation carried forward.
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gotine in patients with advanced PD, with typical dopa-
minergic side-effects and application site reactions
observed, and AEs were comparable with those seen
with ropinirole or pramipexole [12-14,18]. They were
generally mild or moderate in intensity and led to dis-
continuation in 6% patients. There was no apparent rela-
tionship between the incidence of the most common
AEs and the dose of rotigotine, dose of oral DA, or total
DA dose. However, as the number of patients receiving
the different doses was relatively low, it is not possible
to reach conclusions on any potential AE dose-response
relationship. Hallucination was reported as an AE in two
patients, and the incidence of other dopaminergic AEs
including somnolence and impulsive behavior were low
(one patient each), and there were no reports of sleep
attacks. Therefore, taken together with the CGI item
4 results, the combination of low-dose rotigotine with a
low-dose oral DA is likely feasible from a safety perspective.
Numerical improvements in patients’ motor function
(UPDRS III) and ability to carry out ADL (UPDRS II)
were observed following rotigotine add-on therapy. A re-
duction in “off” time was observed, with a corresponding
prolongation of time spent “on” without troublesome
dyskinesia (patient diary). This suggests that the im-
provement in “on” time was not at the expense of
increased dyskinesia. The current study was not de-
signed to investigate the effect of the oral DA formula-
tion (i.e., IR vs ER) on the efficacy outcomes; however,
the formulation of the oral DA did not appear to have
an obvious effect on the improvement in “off” time.
Improvements in the non-motor symptom of sleepdisturbance (PDSS-2, PSQI, and patient diaries), and
PD-related quality of life (PDQ-8) were also observed.
In some patients with PD, symptoms may not be ad-
equately controlled with existing oral DA treatment, and
the dose cannot be sufficiently increased due to adverse
drug reactions. In addition, in some cases, night-time
symptoms may be observed although the current dose
of DA improves day-time symptoms. In the present
study, the patients were taking seemingly low doses
of pramipexole/ropinirole, yet they were receiving
stable doses which were maximal for the individual (i.e.,
“best” pharmacological therapy). The patients were inad-
equately controlled on these doses, and the addition of
rotigotine aimed to further control their symptoms. We
observed that concurrent activation of D2 and D3 recep-
tors following dual DA therapy was feasible, at least in
the dose ranges used. However, the mechanism/s by
which rotigotine added to pramipexole or ropinirole
induced potential benefits on efficacy outcomes (e.g.,
motor control, fluctuations, sleep disturbance) can only
be speculated. They may result from the increase in DA
total dose (i.e., leading to more robust activation of
D2/D3 receptors), the different DA receptor profiles
(i.e., stimulation of D1 receptor, which is unique to rotigo-
tine, combined with D2/D3 activation) and/or the different
pharmacokinetics.
There are some potential limitations to consider. First,
as there was no comparator arm or control group, and
no statistical significance testing was performed, this
limits the conclusions that can be drawn. Second, the
ability to generalize the results of this study is restricted
by the entry criteria of the study, and so limited to
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levodopa and a low-dose oral DA. Third, longer term
safety cannot be concluded from this 8-week study.
Finally, to prevent potential overstimulation of D2/D3
receptor after concomitant use of rotigotine-pramipexole
and rotigotine-ropinirole, less than half of the respective
approved maximum doses were used in this study. There-
fore, we cannot conclude whether higher doses may pro-
vide further benefits or be associated with safety concerns.Conclusions
In summary, this study demonstrates that addition of
rotigotine transdermal system to a low-dose oral DA
was feasible and may be associated with clinical benefit
in patients with advanced PD inadequately controlled on
levodopa and a low-dose oral DA. Dual therapy with
rotigotine transdermal system and a low-dose oral DA in
PD may represent a promising approach to treatment.
Equivalent dose should be taken into consideration
when the DAs are used concomitantly, and the max-
imum dose of DAs should not exceed the upper limit of
the approved dose of any of the DAs. Double-blind con-
trolled studies are required to determine the significance
and clinical relevance of these findings.Additional files
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